SonoMotion

Executive Summary

SonoMotion is a privately held US medical device company pioneering a non-invasive platform for kidney stone treatment. Founded in 2013 and headquartered in Charlottesville, VA, the company is developing two core products: Break Wave, for fragmenting stones, and Stone Clear, for repositioning them. These technologies aim to address the significant unmet need in urology by enabling procedures in awake patients within office-based settings, potentially reducing reliance on shock wave lithotripsy, ureteroscopy, and other invasive methods. By improving procedural efficiency and patient comfort, SonoMotion's platform could disrupt the $2B+ kidney stone treatment market. While the company operates in a competitive landscape with established players, its focus on non-invasive, office-based care positions it well for adoption if clinical and regulatory milestones are achieved. The absence of disclosed funding or stage suggests a lean operation, likely approaching pivotal clinical studies or early commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for Break Wave75% success
• Q2 2027Break Wave pivotal trial data readout60% success
• Q3 2026Strategic partnership or licensing deal with major urology device company40% success